et1402l1-cart cells
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 6, 2017 (NCT03349255)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Alpha-fetoglobulinImmunity, passive
AFP immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03888859 | Early Phase 1 (Phase 1) | Dec 6, 2017 | Aeon Therapeutics (Shanghai) Co., Ltd., Jiao Tong University |
| NCT03349255 | Phase 1 | Oct 6, 2017 | Aeon Therapeutics (Shanghai) Co., Ltd., Wuhan University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aeon Therapeutics (Shanghai) Co., Ltd. | For profit | 2 | 1 | 1 | 2017 |
| Jiao Tong University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Wuhan University | Academic/Hospital | 1 | 0 | 1 | 2017 |
3 organizations
Page 1 / 1